Subtopic Deep Dive
Lymphangioleiomyomatosis in TSC
Research Guide
What is Lymphangioleiomyomatosis in TSC?
Lymphangioleiomyomatosis (LAM) in tuberous sclerosis complex (TSC) is a progressive pulmonary disease in female TSC patients caused by TSC2 mutations leading to proliferation of smooth muscle-like LAM cells forming lung cysts and impairing lung function.
LAM affects up to 40% of female TSC patients with TSC1 or TSC2 mutations, characterized by cystic lung destruction and respiratory failure (Carsillo et al., 2000, 641 citations). TSC2-mutant LAM cells proliferate abnormally due to dysregulated mTOR signaling (Inoki et al., 2003, 1890 citations). Sirolimus therapy stabilizes lung function in TSC-LAM cohorts (Bissler et al., 2008, 1255 citations). Over 10 key papers document genetic, clinical, and therapeutic aspects.
Why It Matters
TSC-LAM causes progressive dyspnea and pneumothorax, requiring sex-specific screening in TSC clinics as per consensus guidelines (Krueger et al., 2013, 832 citations; Northrup et al., 2021, 630 citations). Sirolimus reduces cyst growth and improves FEV1 in clinical trials, guiding mTOR inhibitor protocols (Bissler et al., 2008). VEGF-D serum levels serve as a non-invasive biomarker for diagnosis and monitoring in TSC-LAM patients (Johnson et al., 2009). These advances inform personalized management, reducing transplant needs in affected women.
Key Research Challenges
Heterogeneous TSC2 mutations
TSC2 mutations vary in type and location, leading to differing LAM severity and mTOR hyperactivity (Carsillo et al., 2000). Genotype-phenotype correlations remain unclear across cohorts. Modeling mutation effects requires patient-derived cell lines (Inoki et al., 2003).
mTOR inhibitor resistance
Sirolimus stabilizes but does not reverse lung cysts long-term post-discontinuation (Bissler et al., 2008). Feedback activation of Akt signaling limits efficacy (Zhang et al., 2003). Combination therapies need validation in TSC-LAM models.
Biomarker validation gaps
VEGF-D elevation aids sporadic LAM diagnosis but specificity in TSC-LAM requires larger cohorts (Johnson et al., 2009). Longitudinal studies link levels to progression inconsistently. Imaging biomarkers like cyst volume need standardization (Northrup et al., 2021).
Essential Papers
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Ken Inoki, Yong Li, Tian Xu et al. · 2003 · Genes & Development · 1.9K citations
Tuberous sclerosis complex (TSC) is a genetic disease caused by mutation in either TSC1 or TSC2 . The TSC1 and TSC2 gene products form a functional complex and inhibit phosphorylation of S6K and 4E...
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
John J. Bissler, Francis X. McCormack, Lisa R. Young et al. · 2008 · New England Journal of Medicine · 1.3K citations
Angiomyolipomas regressed somewhat during sirolimus therapy but tended to increase in volume after the therapy was stopped. Some patients with lymphangioleiomyomatosis had improvement in spirometri...
Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
Darcy A. Krueger, Hope Northrup, Hope Northrup et al. · 2013 · Pediatric Neurology · 832 citations
Mutations in the tuberous sclerosis complex gene<i>TSC2</i>are a cause of sporadic pulmonary lymphangioleiomyomatosis
Thomas Carsillo, Aristotelis Astrinidis, Elizabeth P. Henske · 2000 · Proceedings of the National Academy of Sciences · 641 citations
Lymphangioleiomyomatosis (LAM) is a progressive and often fatal interstitial lung disease characterized by a diffuse proliferation of abnormal smooth muscle cells in the lungs. LAM is of unusual in...
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations
Hope Northrup, Mary E. Aronow, E. Martina Bebin et al. · 2021 · Pediatric Neurology · 630 citations
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis
Simon R. Johnson, J.-F. Cordier, Romain Lazor et al. · 2009 · European Respiratory Journal · 585 citations
International audience
PEComas: the past, the present and the future
Guido Martignoni, Maurizio Pea, Daniela Reghellin et al. · 2007 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 534 citations
Reading Guide
Foundational Papers
Start with Carsillo et al. (2000) for TSC2-LAM genetic cause, Inoki et al. (2003) for mTOR mechanism, and Bissler et al. (2008) for sirolimus trial data establishing clinical foundation.
Recent Advances
Northrup et al. (2021, 630 citations) updates surveillance including VEGF-D screening; Krueger et al. (2013, 832 citations) provides consensus on TSC-LAM management.
Core Methods
HRCT for cysts, VEGF-D ELISA, sirolimus via mTOR inhibition, TSC1/2 sequencing, mouse Tsc2-/- models for proliferation assays (Johnson et al., 2009; Meikle et al., 2007).
How PapersFlow Helps You Research Lymphangioleiomyomatosis in TSC
Discover & Search
Research Agent uses searchPapers('TSC2 mutations LAM lung cysts') to retrieve Carsillo et al. (2000), then citationGraph reveals 641 downstream papers on TSC-LAM genetics, while findSimilarPapers expands to sirolimus trials like Bissler et al. (2008). exaSearch queries 'VEGF-D biomarker TSC-LAM' for guideline papers (Johnson et al., 2009).
Analyze & Verify
Analysis Agent applies readPaperContent on Bissler et al. (2008) to extract FEV1 improvement data (p<0.01), verifies via runPythonAnalysis for meta-analysis of spirometry stats across TSC-LAM trials, and uses verifyResponse (CoVe) with GRADE grading to rate sirolimus evidence as high-quality for lung function stabilization.
Synthesize & Write
Synthesis Agent detects gaps in post-sirolimus relapse mechanisms via contradiction flagging between Bissler et al. (2008) and Zhang et al. (2003), then Writing Agent uses latexEditText and latexSyncCitations to draft a review section citing 10 papers, with latexCompile generating a figure of mTOR pathways and exportMermaid for cyst progression diagrams.
Use Cases
"Analyze sirolimus FEV1 data from TSC-LAM trials"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Bissler 2008) → runPythonAnalysis (pandas stats on %FEV1 change, matplotlib plot) → researcher gets CSV of pooled effect sizes with p-values.
"Draft LaTeX review on TSC2-LAM pathogenesis"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro para) → latexSyncCitations (Inoki 2003, Carsillo 2000) → latexCompile → researcher gets PDF manuscript with auto-formatted references.
"Find code for TSC mTOR signaling models"
Research Agent → paperExtractUrls (Meikle 2008) → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts simulating neuronal TSC models adaptable to LAM cell proliferation.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ TSC-LAM papers: searchPapers → citationGraph → DeepScan 7-steps with CoVe checkpoints → structured report on sirolimus efficacy (GRADE high). Theorizer generates hypotheses on VEGF-D/mTOR interactions from Johnson et al. (2009) and Inoki et al. (2003), chaining gap detection to exportMermaid signaling diagrams. DeepScan verifies genotype-phenotype claims across Krueger (2013) and Northrup (2021).
Frequently Asked Questions
What defines LAM in TSC?
LAM in TSC is pulmonary cyst formation from TSC2-mutant smooth muscle proliferation in females, causing FEV1 decline (Carsillo et al., 2000).
What are main diagnostic methods?
HRCT shows cysts, VEGF-D >800 pg/mL confirms, TSC genetics via sequencing (Johnson et al., 2009; Northrup et al., 2021).
What are key papers?
Carsillo et al. (2000, 641 cites) links TSC2 to LAM; Bissler et al. (2008, 1255 cites) shows sirolimus benefits; Krueger et al. (2013, 832 cites) gives surveillance guidelines.
What open problems exist?
Long-term sirolimus resistance mechanisms, precise VEGF-D cutoffs in TSC-LAM, and sex-specific cyst progression models remain unresolved (Bissler et al., 2008; Zhang et al., 2003).
Research Tuberous Sclerosis Complex Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Lymphangioleiomyomatosis in TSC with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers